Cameron Durrant

1.0k total citations
14 papers, 81 citations indexed

About

Cameron Durrant is a scholar working on Infectious Diseases, Epidemiology and Genetics. According to data from OpenAlex, Cameron Durrant has authored 14 papers receiving a total of 81 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Epidemiology and 3 papers in Genetics. Recurrent topics in Cameron Durrant's work include COVID-19 Clinical Research Studies (4 papers), CAR-T cell therapy research (3 papers) and Long-Term Effects of COVID-19 (3 papers). Cameron Durrant is often cited by papers focused on COVID-19 Clinical Research Studies (4 papers), CAR-T cell therapy research (3 papers) and Long-Term Effects of COVID-19 (3 papers). Cameron Durrant collaborates with scholars based in United States, United Kingdom and Australia. Cameron Durrant's co-authors include Khaled M Sarraf, Gail Williams, Aref Al‐Kali, Ayalew Tefferi, Ted Shih, Abhishek A. Mangaonkar, David A. Sallman, Rami S. Komrokji, Naseema Gangat and Eric Padron and has published in prestigious journals such as Blood, CHEST Journal and Thorax.

In The Last Decade

Cameron Durrant

12 papers receiving 79 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cameron Durrant United States	5	27	21	18	17	11	14	81
Lee Ping Chew Malaysia	5	35 1.3×	24 1.1×	5 0.3×	13 0.8×	7 0.6×	26	82
Sæmundur Rögnvaldsson Iceland	5	31 1.1×	20 1.0×	19 1.1×	23 1.4×	15 1.4×	17	61
М. Б. Белогурова Russia	6	7 0.3×	18 0.9×	47 2.6×	22 1.3×	8 0.7×	41	120
Shaimaa El‐Ashwah Egypt	4	19 0.7×	7 0.3×	22 1.2×	10 0.6×	4 0.4×	31	55
Selim Jennane Morocco	5	11 0.4×	10 0.5×	10 0.6×	4 0.2×	6 0.5×	16	40
Jan‐Michel Heger Germany	6	15 0.6×	7 0.3×	56 3.1×	9 0.5×	12 1.1×	23	82
Ryan Malcolm Hum United Kingdom	6	22 0.8×	6 0.3×	6 0.3×	8 0.5×	16 1.5×	19	91
Nazire Pınar Acar Türkiye	7	7 0.3×	8 0.4×	10 0.6×	18 1.1×	7 0.6×	18	110
Albert Collignon France	4	25 0.9×	30 1.4×	11 0.6×	11 0.6×	9 0.8×	9	80
Ana Gorosquieta Spain	4	22 0.8×	12 0.6×	8 0.4×	27 1.6×	8 0.7×	9	58

Countries citing papers authored by Cameron Durrant

Since Specialization

Citations

This map shows the geographic impact of Cameron Durrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cameron Durrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cameron Durrant more than expected).

Fields of papers citing papers by Cameron Durrant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cameron Durrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cameron Durrant. The network helps show where Cameron Durrant may publish in the future.

Co-authorship network of co-authors of Cameron Durrant

This figure shows the co-authorship network connecting the top 25 collaborators of Cameron Durrant. A scholar is included among the top collaborators of Cameron Durrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cameron Durrant. Cameron Durrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Temesgen, Zelalem, Colleen F. Kelley, Frank Cerasoli, et al.. (2022). C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial. Thorax. 78(6). thoraxjnl–2022. 8 indexed citations

Kenderian, Saad S., Cameron Durrant, Dale Chappell, Omar Abdihamid, & Adrian Kilcoyne. (2021). A Phase 2/3 Randomized, Placebo-Controlled, Open-Label, Multi-Center Trial of Lenzilumab to Improve the Safety and Efficacy of CAR-T Cell Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma (The SHIELD Study). Blood. 138(Supplement 1). 1758–1758. 5 indexed citations

Temesgen, Zelalem, Jason V. Baker, Christopher Polk, et al.. (2021). S48 Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial. A34.1–A34. 1 indexed citations

Temesgen, Zelalem, Charles D. Burger, Jason V. Baker, et al.. (2021). C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL. CHEST Journal. 160(4). A2522–A2524.

Burger, Charles D., Jason V. Baker, Christopher Polk, et al.. (2021). 40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial. Open Forum Infectious Diseases. 8(Supplement_1). S29–S29.

Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2020). Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 136(7). 909–913. 31 indexed citations

Cox, Michelle J., Rosalie M. Sterner, Reona Sakemura, et al.. (2020). Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. Biology of Blood and Marrow Transplantation. 26(3). S60–S61. 3 indexed citations

Chen, Hansheng, C. B. Cooper, Cameron Durrant, et al.. (2019). Graded Microstructure of Additive Manufactured Ti-6Al-4V via Electron Beam Melting. Microscopy and Microanalysis. 25(S2). 498–499. 1 indexed citations

Cox, Michelle J., Rosalie M. Sterner, Reona Sakemura, et al.. (2019). Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. Blood. 134(Supplement_1). 3868–3868. 3 indexed citations

10.

Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2019). A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood. 134(Supplement_1). 4234–4234. 3 indexed citations

11.

Gan, Hui, Lawrence Cher, Zarnie Lwin, et al.. (2019). ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology. 21(Supplement_6). vi6–vi6. 4 indexed citations

12.

Beale, Amanda, et al.. (2017). P458 Sleep problems in inflammatory bowel disease; When bed becomes a battleground. Journal of Crohn s and Colitis. 11(suppl_1). S311–S311. 1 indexed citations

13.

Durrant, Cameron, et al.. (2008). Thermal injury – The first 24 h. Current Anaesthesia and Critical Care. 19(5-6). 256–263. 9 indexed citations

14.

Durrant, Cameron, et al.. (2008). Chemical burns: A review. Current Anaesthesia and Critical Care. 19(5-6). 282–286. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact